Open Access. Powered by Scholars. Published by Universities.®
- File Type
Articles 1 - 3 of 3
Full-Text Articles in Medicine and Health Sciences
The Relationship Between Vascularity, P53 Gene Mutations And Distant Metastatic Disease In Epithelial Ovarian Carcinoma, Janna Girardi, Megan Samuelson, Anna Button, Koen De Geest, David P. Bender, Amina Ahmed, Michael Goodheart
The Relationship Between Vascularity, P53 Gene Mutations And Distant Metastatic Disease In Epithelial Ovarian Carcinoma, Janna Girardi, Megan Samuelson, Anna Button, Koen De Geest, David P. Bender, Amina Ahmed, Michael Goodheart
David P Bender
Mutations of the p53 tumor suppressor gene are associated with large differences (>7 vessels/HPF) in Microvessel density (MVD) counts between primary and metastatic tumor sites in patients with epithelial ovarian cancer. These data are consistent with models demonstrating p53 mutation functions directly to influence angiogenesis. This information supports continued therapy and research involving angiogenesis inhibitors in patients with ovarian cancer, especially in the setting of increased differences in MVD between primary and metastatic sites.
The Combination Of Paclitaxel And Gefitinib Inhibits Endometrial Cancer Cells By Inducing Mitotic Catastrophe: Proof Of Principle For Dual Therapy In Endometrial Cancer, Xiangbing Meng, Laura Laidler, Lina Albitar, Anna Holmes, Donghai Dai, Thomas Buekers, David Bender, Kimberly Leslie
The Combination Of Paclitaxel And Gefitinib Inhibits Endometrial Cancer Cells By Inducing Mitotic Catastrophe: Proof Of Principle For Dual Therapy In Endometrial Cancer, Xiangbing Meng, Laura Laidler, Lina Albitar, Anna Holmes, Donghai Dai, Thomas Buekers, David Bender, Kimberly Leslie
David P Bender
Serous uterine endometrial cancer is a lethal disease for which new therapeutic regimens are urgently needed. Combinations of chemotherapeutic agents and small molecule growth factor inhibitors have demonstrated activity in cancers from other sites. Our objective was to determine whether such a combination using Paclitaxel and Gefitinib could be active in serous endometrial cancer cells.
Comparison Of P53 Mutation Status, Primary Cytoreductive Surgical Outcomes, And Overall Survival In Patients With Ovarian Cancer, David Engle, Hubert Fornalik, Traci Neff, Anna Button, K Collins, Amina Ahmed, David Bender, Susan Lutgendorf, Michael Goodheart
Comparison Of P53 Mutation Status, Primary Cytoreductive Surgical Outcomes, And Overall Survival In Patients With Ovarian Cancer, David Engle, Hubert Fornalik, Traci Neff, Anna Button, K Collins, Amina Ahmed, David Bender, Susan Lutgendorf, Michael Goodheart
David P Bender
Optimal surgical cytoreduction continues to be an important prognostic variable in patients with ovarian cancer independent of p53 mutational status. Among patients with suboptimal cytoreduction a p53 mutation may offer a survival advantage.